# Zenapax to Treat Multiple Sclerosis

> **NCT00001934** · PHASE2 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 22 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Zenapax

## Key facts

- **NCT ID:** NCT00001934
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 2005-08
- **Final completion:** 2008-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2011-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001934, "Zenapax to Treat Multiple Sclerosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00001934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*